DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Samidorphan is an investigational drug.
There have been 6 clinical trials for Samidorphan. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Schizophrenia, Disease, and Alcoholism. The leading clinical trial sponsors are Alkermes, Inc. and [disabled in preview].
There are forty-four US patents protecting this investigational drug and two hundred and thirty-eight international patents.
Recent Clinical Trials for Samidorphan
|Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder||Alkermes, Inc.||Phase 1|
|A Phase 1 Safety Study in Adults With Schizophrenia||Alkermes, Inc.||Phase 1|
|A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers||Alkermes, Inc.||Phase 1|
Top disease conditions for Samidorphan
Top clinical trial sponsors for Samidorphan
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Samidorphan||⤷ Try it Free||Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof||⤷ Try it Free|
|Samidorphan||⤷ Try it Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||⤷ Try it Free|
|Samidorphan||⤷ Try it Free||Compositions of buprenorphine and .mu. antagonists||Alkermes Pharma Ireland Limited (Dublin, IE)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Samidorphan||European Patent Office||EP3324975||2035-07-22||⤷ Try it Free|
|Samidorphan||European Patent Office||EP3801545||2035-07-22||⤷ Try it Free|
|Samidorphan||World Intellectual Property Organization (WIPO)||WO2017015309||2035-07-22||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|